Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dexcom Stocks Continue To Drop After Short-Seller Warns of Competition From Abbott

Executive Summary

Investment managing firm Spruce Point says factors such as patients hacking their older Dexcom continuous glucose meters, the company’s decision to not disclose its patient base and competition from Abbott’s upcoming Libre 2 CGMs are red flags that Dexcom is overstating its market potential. Dexcom's stocks lost a fifth of their value after the short-seller released a recent report that says the firm is overvalued.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts